Cognition Therapeutics, Inc. Preferred Stock, Accretion of Redemption Discount
Cognition Therapeutics, Inc. (CGTX) reported Preferred Stock, Accretion of Redemption Discount of $2.44 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-30.
Discontinued › Shareholders' Equity
us-gaap:PreferredStockAccretionOfRedemptionDiscount · last filed 2022-03-30
- Cognition Therapeutics, Inc. preferred stock, accretion of redemption discount for the quarter ending 2020-09-30 was $337.00K.
- Cognition Therapeutics, Inc. preferred stock, accretion of redemption discount for the quarter ending 2020-06-30 was $1.05M.
- Cognition Therapeutics, Inc. preferred stock, accretion of redemption discount for the quarter ending 2020-03-31 was $1.05M.
- Cognition Therapeutics, Inc. preferred stock, accretion of redemption discount for fiscal 2020 was $2.44M.
| Period end | Preferred Stock, Accretion of Redemption Discount 3 month | Preferred Stock, Accretion of Redemption Discount 6 month | Preferred Stock, Accretion of Redemption Discount 9 month | Preferred Stock, Accretion of Redemption Discount 12 month |
|---|---|---|---|---|
| 2020-12-31 | $2.44M 10-K · filed 2022-03-30 | |||
| 2020-09-30 | $337.00K 10-Q · filed 2021-11-17 | $1.39M derived: sum of 2 quarters · filed 2021-11-17 | $2.44M derived: sum of 3 quarters · filed 2021-11-17 | |
| 2020-06-30 | $1.05M 10-Q · filed 2021-11-17 | $2.11M derived: sum of 2 quarters · filed 2021-11-17 | ||
| 2020-03-31 | $1.05M 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |